An Irvine, CA-based clinical-stage biopharmaceutical company announced the completion of a $60 million, Series B financing, led by Vivo Capital and included Frazier Healthcare Partners, Flying L Partners, Visionary Ventures, Aperture Venture Partners, and Horowitz Group. The drug was founded based on conducting research to take a drug for Demodex blepharitis, an important unmet need and one of the largest diseases in anterior segment medicine.
When was Tarsus Founded?
What Condition are they targeting?
They are a new upstart targeting the blepharitis market. They report that there are 30 million people in the US with ocular surface disease; 20 million with blepharitis and 9 million with Demodex Blepharitis.
Blepharitis, a common ocular condition, is characterized by inflammation, scaling, reddening and crusting of the eyelid and can also cause burning, itching or a grainy sensation when introducing foreign objects or substances in the eye. Although not sight-threatening, it can lead to permanent alterations. Different variations of blepharitis can be classified as seborrheic, staphylococcal, mixed, posterior or meibomitis, or parasitic. In a survey of American ophthalmologists and optometrists report that 37% to 47% of patients seen by those served had signs of blepharitis, which can impact all ages and ethnic groups. One single-center of 90 patients with chronic blepharitis found that the average age of patients was 50 years old.
The leadership seeks to lead this venture to create the first ever drug for blepharitis. TrialSite News estimates they currently employ between 10 and 15 employees.